Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Bernardete, Weber; Bersch, Ferreira  C; Torreglosa, Camila R; Marcadenti, Aline; Lara, Enilda S; Silva, Jaqueline T da; Costa, Rosana P; Santos, Renato H N; Berwanger, Otavio; Bosquetti, Rosa; Pagano, Raira; Mota, Luis G S; Oliveira, Juliana D de; Soares, Rafael M; Galante, Andrea P; Silva, Suzana A da; Zampieri, Fernando G; Kovacs, Cristiane; Amparo, Fernanda C; Moreira, Priscila; Silva, Renata A da; Santos, Karina G dos; Monteiro, Aline S5,; Paiva, Catharina C J; Magnoni, Carlos D; Moreira, Annie S; Peçanha, Daniela O; Missias, Karina C S; Paula, Lais S de; Marotto, Deborah; Souza, Paula; Martins, Patricia R T; Santos, Elisa M dos; Santos, Michelle R; Silva, Luisa P; Torres, Rosileide S; Barbosa, Socorro N A A; Pinho, Priscila M de; Araujo, Suzi H A de; Veríssimo, Adriana O L; Guterres, Aldair S; Cardoso, Andrea F R; Palmeira, Moacyr M; Ataíde, Bruno R B de; Costa, Lilian P S; Marinho, Helyde A; Araújo, Celme B P de; Carvalho, Helen M S; Maquiné, Rebecca O; Caiado, Alessandra C; Matos, Cristina H de; Barretta, Claiza; Specht, Clarice M; Onofrei, Mihaela; Bertacco, Renata T A; Borges, Lucia R; Bertoldi, Eduardo G; Longo, Aline; Ribas, Bruna L P; Dobke, Fernanda; Pretto, Alessandra D B; Bachettini, Nathalia P; Gastaud, Alexandre; Necchi, Rodrigo; Souza, Gabriela C; Zuchinali, Priccila; Fracasso, Bianca M; Bobadra, Sara; Sangali, Tamirys D; Salamoni, Joyce; Garlini, Luíza M; Shirmann, Gabriela S; Los Santos, Mônica L P de; Bortonili, Vera M S; Santos, Cristiano P dos; Bragança, Guilherme C M; Ambrózio, Cíntia L; Lima, Susi B E; Schiavini, Jéssica; Napparo, Alechandra S; Boemo, Jorge L; Nagano, Francisca E Z; Modanese, Paulo V G; Cunha, Natalia M; Frehner, Caroline; Silva, Lannay F da; Formentini, Franciane S; Ramos, Maria E M; Ramos, Salvador S; Lucas, Marilia C S; Machado, Bruna G; Ruschel, Karen B; Beiersdorf, Jâneffer R; Nunes, Cristine E; Rech, Rafael L; Damiani, Mônica; Berbigier, Marina; Poloni, Soraia; Vian, Izabele; Russo, Diana S; Rodrigues, Juliane; Moraes, Maria A P de; Costa, Laura M da; Boklis, Mirena; El Kik, Raquel M; Adorne, Elaine F; Teixeira, Joise M; Trescastro, Eduardo P; Chiesa, Fernanda L; Telles, Cristina T; Pellegrini, Livia A; Reis, Lucas F; Cardoso, Roberta G M; Closs, Vera E; Feres, Noel H; Silva, Nilma F da; Silva, Neyla E; Dutra, Eliane S; Ito, Marina K; Lima, Mariana E P; Carvalho, Ana P P F; Taboada, Maria I S; Machado, Malaine M A; David, Marta M; Júnior, Délcio G S; Dourado, Camila; Fagundes, Vanessa C F O; Uehara, Rose M; Sasso, Sandramara; Vieira, Jaqueline S O; Oliveira, Bianca A S de; Pereira, Juliana L; Rodrigues, Isa G; Pinho, Claudia P S; Sousa, Antonio C S; Almeida, Andreza S; Jesus, Monique T de; Silva, Glauber B da; Alves, Lucicna V S; Nascimento, Viviane O G; Vieira, Sabrina A; Coura, Amanda G L; Dantas, Clenise F; Leda, Neuma M F S; Medeiros, Auriene L; Andrade, Ana C L; Pinheiro, Josilene M F; Lima, Luana R M de; Sabino, L S; Souza, C V S de; Vasconcelos, S M L; Costa, F A; Ferreira, R C; Cardoso, I B; Navarro, L N P; Ferreira, R B; Júnior, A E S; Silva, M B G; Almeida, K M M; Penafort, A M; Queirós, A P O de; Farias, G M N; Carlos, D M O; Cordeiro, C G N C; Vasconcelos, V B; Araújo, E M V M C de; Sahade, V; Ribeiro, C S A; Araujo, G A; Gonçalves, L B; Teixeira, C S; Silva, L M A J; Costa, L B de; Souza, T S; Jesus, S O de; Luna, A B; Rocha, B R S da; Santos, M A; Neto, J A F; Dias, L P P; Cantanhede, R C A; Morais, J M; Duarte, R C L; Barbosa, E C B; Barbosa, J M A; Sousa, R M L de; Santos, A F dos; Teixeira, A F; Moriguchi, E H; Bruscato, N M; Kesties, J; Vivian, L; Carli, W de; Shumacher, M; Izar, M C O; Asoo, M T; Kato, J T; Martins, C M; Machado, V A; Bittencourt, C R O; Freitas, T T de; Sant'Anna, V A R; Lopes, J D; Fischer, S C P M; Pinto, S L; Silva, K C; Gratão, L H A; Holzbach, L C; Backes, L M; Rodrigues, M P; Deucher, K L A L; Cantarelli, M; Bertoni, V M; Rampazzo, D; Bressan, J; Hermsdorff, H H M; Caldas, A P S; Felício, M B; Honório, C R; Silva, A da; Souza, S R; Rodrigues, P A; Meneses, T M X de; Kumbier, M C C; Barreto, A L; Cavalcanti, A B.
Am. heart j. ; 215: 187-197, Set. 2019. gráfico, tabela
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: biblio-1023356

RESUMO

Background Complex percutaneous coronary intervention (PCI) is associated with higher ischemic risk, which can be mitigated by long-term dual antiplatelet therapy (DAPT). However, concomitant high bleeding risk (HBR) may be present, making it unclear whether short- or long-term DAPT should be prioritized. Objectives This study investigated the effects of ischemic (by PCI complexity) and bleeding (by PRECISE-DAPT [PRE dicting bleeding Complications in patients undergoing stent Implantation and Sub sequent Dual Anti Platelet Therapy] score) risks on clinical outcomes and on the impact of DAPT duration after coronary stenting. Methods Complex PCI was defined as ≥3 stents implanted and/or ≥3 lesions treated, bifurcation stenting and/or stent length >60 mm, and/or chronic total occlusion revascularization. Ischemic and bleeding outcomes in high (≥25) or non-high (<25) PRECISE-DAPT strata were evaluated based on randomly allocated duration of DAPT. Results Among 14,963 patients from 8 randomized trials, 3,118 underwent complex PCI and experienced a higher rate of ischemic, but not bleeding, events. Long-term DAPT in non-HBR patients reduced ischemic events in both complex (absolute risk difference: −3.86%; 95% confidence interval: −7.71 to +0.06) and noncomplex PCI strata (absolute risk difference: −1.14%; 95% confidence interval: −2.26 to −0.02), but not among HBR patients, regardless of complex PCI features. The bleeding risk according to the Thrombolysis In Myocardial Infarction scale was increased by long-term DAPT only in HBR patients, regardless of PCI complexity. Conclusions Patients who underwent complex PCI had a higher risk of ischemic events, but benefitted from long-term DAPT only if HBR features were not present. These data suggested that when concordant, bleeding, more than ischemic risk, should inform decision-making on the duration of DAPT. (AU)


Assuntos
Humanos , Doenças Cardiovasculares/prevenção & controle , Avaliação Nutricional , Alimentos, Dieta e Nutrição
2.
Am Heart J ; 215: 187-197, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31349110

RESUMO

BACKGROUND: Appropriate dietary recommendations represent a key part of secondary prevention in cardiovascular disease (CVD). We evaluated the effectiveness of the implementation of a nutritional program on quality of diet, cardiovascular events, and death in patients with established CVD. METHODS: In this open-label, multicenter trial conducted in 35 sites in Brazil, we randomly assigned (1:1) patients aged 45 years or older to receive either the BALANCE Program (experimental group) or conventional nutrition advice (control group). The BALANCE Program included a unique nutritional education strategy to implement recommendations from guidelines, adapted to the use of affordable and regional foods. Adherence to diet was evaluated by the modified Alternative Healthy Eating Index. The primary end point was a composite of all-cause mortality, cardiovascular death, cardiac arrest, myocardial infarction, stroke, myocardial revascularization, amputation, or hospitalization for unstable angina. Secondary end points included biochemical and anthropometric data, and blood pressure levels. RESULTS: From March 5, 2013, to Abril 7, 2015, a total of 2534 eligible patients were randomly assigned to either the BALANCE Program group (n = 1,266) or the control group (n = 1,268) and were followed up for a median of 3.5 years. In total, 235 (9.3%) participants had been lost to follow-up. After 3 years of follow-up, mean modified Alternative Healthy Eating Index (scale 0-70) was only slightly higher in the BALANCE group versus the control group (26.2 ±â€¯8.4 vs 24.7 ±â€¯8.6, P < .01), mainly due to a 0.5-serving/d greater intake of fruits and of vegetables in the BALANCE group. Primary end point events occurred in 236 participants (18.8%) in the BALANCE group and in 207 participants (16.4%) in the control group (hazard ratio, 1.15; 95% CI 0.95-1.38; P = .15). Secondary end points did not differ between groups after follow-up. CONCLUSIONS: The BALANCE Program only slightly improved adherence to a healthy diet in patients with established CVD and had no significant effect on the incidence of cardiovascular events or death.

3.
Clin Cardiol ; 41(3): 392-399, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29569254

RESUMO

BACKGROUND: Left ventricular ejection fraction (LVEF) is a major determinant of long-term prognosis after ST-segment elevation myocardial infarction (STEMI). STEMI patients with reduced LVEF have a poor prognosis, despite successful reperfusion and the use of renin-angiotensin-aldosterone inhibitors. HYPOTHESIS: Intracoronary infusion of bone marrow-derived mononuclear cells (BMMC) may improve LVEF in STEMI patients successfully reperfused. METHODS: The main inclusion criteria for this double-blind, randomized, multicenter study were patient age 30 to 80 years, LVEF ≤50%, successful angioplasty of infarct-related artery, and regional dysfunction in the infarct-related area analyzed before cell injection. Cardiac magnetic resonance imaging was used to assess LVEF, left ventricular volumes, and infarct size at 7 to 9 days and 6 months post-myocardial infarction. RESULTS: One hundred and twenty-one patients were included (66 patients in the BMMC group and 55 patients in the placebo group). The primary endpoint, mean LVEF, was similar between both groups at baseline (44.63% ± 10.74% vs 42.23% ± 10.33%; P = 0.21) and at 6 months (44.74% ± 12.95 % vs 43.50 ± 12.43%; P = 0.59). The groups were also similar regarding the difference between baseline and 6 months (0.11% ± 8.5% vs 1.27% ± 8.93%; P = 0.46). Other parameters of left ventricular remodeling, such as systolic and diastolic volumes, as well as infarct size, were also similar between groups. CONCLUSIONS: In this randomized, multicenter, double-blind trial, BMMC intracoronary infusion did not improve left ventricular remodeling or decrease infarct size.


Assuntos
Ventrículos do Coração/diagnóstico por imagem , Infarto do Miocárdio com Supradesnível do Segmento ST/terapia , Transplante de Células-Tronco/métodos , Volume Sistólico/fisiologia , Função Ventricular Esquerda/fisiologia , Remodelação Ventricular/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Feminino , Seguimentos , Ventrículos do Coração/fisiopatologia , Humanos , Imagem Cinética por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Infarto do Miocárdio com Supradesnível do Segmento ST/diagnóstico , Infarto do Miocárdio com Supradesnível do Segmento ST/fisiopatologia
4.
EGEMS (Wash DC) ; 3(2): 1165, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26290892

RESUMO

BACKGROUND: Clinical guidelines, prediction tools, and computerized decision support (CDS) are underutilized outside of research contexts, and conventional teaching of evidence-based practice (EBP) skills fails to change practitioner behavior. Overcoming these challenges requires traversing practice, policy, and implementation domains. In this article, we describe a program's conceptual design, the results of institutional participation, and the program's evolution. Next steps include integration of instruction in principles of CDS. CONCEPTUAL MODEL: Teaching Evidence Assimilation for Collaborative Health Care (TEACH) is a multidisciplinary annual conference series involving on- and off-site trainings and facilitation within health care provider organizations (HPOs). Separate conference tracks address clinical policy and guideline development, implementation science, and foundational EBP skills. The implementation track uses a model encompassing problem delineation, identifying knowing-doing gaps, synthesizing evidence to address those gaps, adapting guidelines for local use, assessing implementation barriers, measuring outcomes, and sustaining evidence use. Training in CDS principles is an anticipated component within this track. Within participating organizations, the program engages senior administration, middle management, and frontline care providers. On-site care improvement projects serve as vehicles for developing ongoing, sustainable capabilities. TEACH facilitators conduct on-site workshops to enhance project development, integration of stakeholder engagement and decision support. Both on- and off-site components emphasize narrative skills and shared decision-making. EXPERIENCE: Since 2009, 430 participants attended TEACH conferences. Delegations from five centers attended an initial series of three conferences. Improvement projects centered on stroke care, hospital readmissions, and infection control. Successful implementation efforts were characterized by strong support of senior administration, involvement of a broad multidisciplinary constituency within the organization, and on-site facilitation on the part of TEACH faculty. Involvement of nursing management at the senior faculty level led to increased presence of nursing and other disciplines at subsequent conferences. CONCLUSIONS: A multidisciplinary and multifaceted approach to on- and off-site training and facilitation may lead to enhanced use of research to improve the quality of care within HPOs. Such training may provide valuable contextual grounding for effective use of CDS within such organizations.

5.
Cell Transplant ; 18(3): 343-52, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19558782

RESUMO

The objective of this study was to investigate safety and feasibility of autologous bone marrow mononuclear cells (BMMNC) transplantation in ST elevation myocardial infarction (STEMI), comparing anterograde intracoronary artery (ICA) delivery with retrograde intracoronary vein (ICV) approach. An open labeled, randomized controlled trial of 30 patients admitted with STEMI was used. Patients were enrolled if they 1) were successfully reperfused within 24 h from symptoms onset and 2) had infarct size larger than 10% of the left ventricle (LV). One hundred million BMMNC were injected in the infarct-related artery (intra-arterial group) or vein (intravenous group), 1% of which was labeled with Tc(99m)-hexamethylpropylenamineoxime. Cell distribution was evaluated 4 and 24 h after injection. Baseline MRI was performed in order to evaluate microbstruction pattern. Baseline radionuclide ventriculography was performed before cell transfer and after 3 and 6 months. All the treated patients were submitted to repeat coronary angiography after 3 months. Thirty patients (57 +/- 11 years, 70% males) were randomly assigned to ICA (n = 14), ICV (n = 10), or control (n = 6) groups. No serious adverse events related to the procedure were observed. Early and late retention of radiolabeled cells was higher in the ICA than in the ICV group, independently of microcirculation obstruction. An increase of EF was observed in the ICA group (p = 0.02) compared to baseline. Injection procedures through anterograde and retrograde approaches seem to be feasible and safe. BMMNC retention by damaged heart tissue was apparently higher when the anterograde approach was used. Further studies are required to confirm these initial data.


Assuntos
Transplante de Medula Óssea/métodos , Leucócitos Mononucleares/transplante , Infarto do Miocárdio/terapia , Doença Aguda , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Demografia , Feminino , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Nitratos , Ventriculografia com Radionuclídeos , Tecnécio Tc 99m Exametazima , Tecnécio Tc 99m Sestamibi , Transplante Autólogo
6.
J Eval Clin Pract ; 15(6): 891-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20367679

RESUMO

Rationale Evidence-based medicine (EBM) has been acclaimed as a major advance in medical science, but criticized as a proposed alternative model for the practice and teaching of medicine. Ambiguity regarding the proper role of the contributions of EBM within the fabric of medicine and health care has contributed to this discrepancy. Aims and objectives We undertook a critical review of the history of the EBM movement, beginning with its origins in the 1970s and continuing through this century. We drew upon the results of an independent project that rationalized the EBM domain from the perspective of educational evaluation and assessment. We considered the content of EBM in relationship to the propositions and promises embodied in advocacy publications. Results EBM emerged in the context of the explosion of biomedical information in the decade preceding public access to the Internet in the mid-1990s and drew upon the independently derived 'information literacy' formula developed by information scientists during the 1980s. The critically important content and achievements of EBM are fully explained within the confines of the information literacy model. The thesis that EBM offers an alternative paradigm for individualized health care, asserted in the advocacy literature, is not supported by published models of evidence-based clinical practice. Conclusion A critical historical review of the origins, content and development of the EBM movement proposes that full integration of the fruits of the movement into routine clinical care remains a conceptual and practical challenge.


Assuntos
Medicina Baseada em Evidências/história , Biologia Computacional/história , Difusão de Inovações , História do Século XX , História do Século XXI , Humanos , Disseminação de Informação/história
8.
J Eval Clin Pract ; 15(6): 1205-7, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20367728

RESUMO

RATIONALE, AIMS AND OBJECTIVES: To summarize 20-year experience of conducting a workshop designed for educators who wish to improve their teaching skills of evidence based medicine (EBM). The goal is to provide tips for educators interested in replicating this educational model. METHODS: Qualitative description of factors associated with the success of the workshop. RESULTS: The factors considered by instructors to be most helpful are: the small group interactive design, role-play and simulation of real world learning environments, a mentorship model and high educator to learner ratio. CONCLUSIONS: Although this experience is observational and does not represent high quality evidence, certain attributes in the design of EBM workshops may lead to better dissemination of EBM concepts. Educators may consider empirically applying some of these attributes and testing their efficacy in comparative studies.


Assuntos
Medicina Baseada em Evidências/educação , Desenvolvimento de Pessoal , Ensino , Currículo , Educação , Humanos , Avaliação de Programas e Projetos de Saúde
9.
Trials ; 9: 41, 2008 Jul 03.
Artigo em Inglês | MEDLINE | ID: mdl-18598362

RESUMO

BACKGROUND: Myocardial infarction remains as a major cause of mortality worldwide and a high rate of survivors develop heart failure as a sequel, resulting in a high morbidity and elevated expenditures for health system resources. We have designed a multicenter trial to test for the efficacy of autologous bone marrow (ABM) mononuclear cell (MC) transplantation in this subgroup of patients. The main hypothesis to be tested is that treated patients will have a significantly higher ejection fraction (EF) improvement after 6 months than controls. METHODS: A sample of 300 patients admitted with ST elevation acute myocardial infarction (STEMI) and left ventricle (LV) systolic dysfunction, and submitted to successful mechanical or chemical recanalization of the infarct-related coronary artery will be selected for inclusion and randomized to either treated or control group in a double blind manner. The former group will receive 100 x 106 MC suspended in saline with 5% autologous serum in the culprit vessel, while the latter will receive placebo (saline with 5% autologous serum). IMPLICATIONS: Many phase I/II clinical trials using cell therapy for STEMI have been reported, demonstrating that cell transplantation is safe and may lead to better preserved LV function. Patients with high risk to develop systolic dysfunction have the potential to benefit more. Larger randomized, double blind and controlled trials to test for the efficacy of cell therapies in patients with high risk for developing heart failure are required. TRIAL REGISTER: This trial is registered at the NIH registry under the number NCT00350766.

10.
C R Biol ; 330(6-7): 543-9, 2007 Jun-Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17631451

RESUMO

We describe cell therapy for severe ischemic heart failure using transendocardial injection of autologous bone-marrow-derived mononuclear cells. The treated patients had significantly less heart failure and angina, sustained significant improvement of pumping power, exercise capacity, cardiac muscle irrigation, and blood supply to the body. Electrical and mechanical mappings of the myocardium before and after the therapy, and anatomopathological examination of the myocardium of one of the patients that had deceased of a stroke eleven months after the treatment indicated sustained neoangiogenesis and improvement of activity and quantity of cardiomyocytes in the injected regions. Post-hoc analyses of injected cell phenotype and improvement of myocardial function indicate that presence of CD8+ and CD56+ cells does not correlate with good prognostics, suggesting a possibility of cell selection. For 'no-option' severe cardiac patients, significant benefits of cell therapy and absence of adverse effects may justify the application of bone-marrow-derived cell therapy.


Assuntos
Transplante de Medula Óssea , Isquemia Miocárdica/terapia , Animais , Eletrofisiologia , Humanos , Miócitos Cardíacos/transplante
11.
Trials ; 8: 2, 2007 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-17233910

RESUMO

BACKGROUND: Cardiovascular diseases are the major cause of death in the world. Current treatments have not been able to reverse this scenario, creating the need for the development of new therapies. Cell therapies have emerged as an alternative for cardiac diseases of distinct causes in experimental animal studies and more recently in clinical trials. METHOD/DESIGN: We have designed clinical trials to test for the efficacy of autologous bone marrow derived mononuclear cell therapies in four different cardiopathies: acute and chronic ischemic heart disease, and Chagasic and dilated cardiomyopathy. All trials are multicenter, randomized, double-blind and placebo controlled. In each trial 300 patients will be enrolled and receive optimized therapy for their specific condition. Additionally, half of the patients will receive the autologous bone marrow cells while the other half will receive placebo (saline with 5% autologous serum). For each trial there are specific inclusion and exclusion criteria and the method for cell delivery is intramyocardial for the chronic ischemic heart disease and intracoronary for all others. Primary endpoint for all studies will be the difference in ejection fraction (determined by Simpson's rule) six and twelve months after intervention in relation to the basal ejection fraction. The main hypothesis of this study is that the patients who receive the autologous bone-marrow stem cell implant will have after a 6 month follow-up a mean increase of 5% in absolute left ventricular ejection fraction in comparison with the control group. DISCUSSION: Many phase I clinical trials using cell therapy for cardiac diseases have already been performed. The few randomized studies have yielded conflicting results, rendering necessary larger well controlled trials to test for efficacy of cell therapies in cardiopathies. The trials registration numbers at the NIH registry are the following: Chagasic cardiomyopathy (NCT00349271), dilated cardiomyopathy (NCT00333827), acute myocardial infarction (NCT00350766) and Chronic Ischemic Heart Disease (NCT00362388).

12.
Circulation ; 112(4): 521-6, 2005 Jul 26.
Artigo em Inglês | MEDLINE | ID: mdl-16027258

RESUMO

BACKGROUND: Cell-based therapies for treatment of ischemic heart disease are currently under investigation. We previously reported the results of a phase I trial of transendocardial injection of autologous bone marrow mononuclear (ABMM) cells in patients with end-stage ischemic heart disease. The current report focuses on postmortem cardiac findings from one of the treated patients, who died 11 months after cell therapy. METHODS AND RESULTS: Anatomicopathologic, morphometric, and immunocytochemical findings from the anterolateral ventricular wall (with cell therapy) were compared with findings from the interventricular septum (normal perfusion and no cell therapy) and from the inferoposterior ventricular wall (extensive scar tissue and no cell therapy). No signs of adverse events were found in the cell-injected areas. Capillary density was significantly higher (P<0.001) in the anterolateral wall than in the previously infarcted tissue in the posterior wall. The prominent vasculature of the anterolateral wall was associated with hyperplasia of pericytes, mural cells, and adventitia. Some of these cells had acquired cytoskeletal elements and contractile proteins (troponin, sarcomeric alpha-actinin, actinin), as well as the morphology of cardiomyocytes, and appeared to have migrated toward adjacent bundles of cardiomyocytes. CONCLUSIONS: Eleven months after treatment, morphological and immunocytochemical analysis of the sites of ABMM cell injection showed no abnormal cell growth or tissue lesions and suggested that an active process of angiogenesis was present in both the fibrotic cicatricial tissue and the adjacent cardiac muscle. Some of the pericytes had acquired the morphology of cardiomyocytes, suggesting long-term sequential regeneration of the cardiac vascular tree and muscle.


Assuntos
Células da Medula Óssea/citologia , Transplante de Medula Óssea , Insuficiência Cardíaca/terapia , Isquemia Miocárdica/terapia , Miocárdio/patologia , Transplante de Células-Tronco , Desmina/análise , Insuficiência Cardíaca/patologia , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/patologia , Neovascularização Fisiológica , Tomografia Computadorizada de Emissão de Fóton Único , Transplante Autólogo
13.
Arq Bras Cardiol ; 84(5): 360-6, 2005 May.
Artigo em Português | MEDLINE | ID: mdl-15917966

RESUMO

OBJECTIVE: This study aimed at assessing the effects of autologous transendocardial transplantation of bone marrow mononuclear cells (ATTBMMC) on symptoms, exercise capacity, myocardial perfusion and contractility in patients with severe ischemic heart disease during a 6-month follow-up period. METHODS: This prospective study comprised 21 patients as follows: the first 14 patients forming the treated group, and the last 7 patients forming the control group. Initially, all patients underwent clinical and laboratory assessment, treadmill testing, echocardiography, myocardial scintigraphy, and 24-hour Holter. The bone marrow mononuclear cells (BMMC) were isolated, washed, and diluted in 0.9% saline solution for transendocardial injection in areas of viable myocardium in the treated group, (15 0.2-mL injections). All patients were reassessed in the end of 2 and 6 months of follow-up. RESULTS: The demographic data and other characteristics did not significantly differ between the groups in the initial evaluation. No major adverse events related to the ATTBMMC were observed. In the end of 6 months, a reduction in the ischemic area was observed on nuclear perfusion imaging (P=0.05), as was a significant improvement in symptoms, functional capacity, and left ventricular overall function. CONCLUSION: This study showed that transendocardial injections of BMMC are safe in human beings with ischemic heart disease associated with severe ventricular dysfunction. The effects observed in the short run were maintained up to the sixth month of follow-up.


Assuntos
Transplante de Medula Óssea , Tolerância ao Exercício/fisiologia , Isquemia Miocárdica/cirurgia , Estudos Epidemiológicos , Teste de Esforço , Feminino , Coração/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Contração Miocárdica , Isquemia Miocárdica/diagnóstico por imagem , Neovascularização Fisiológica , Cintilografia , Transplante Autólogo
14.
Arq. bras. cardiol ; 84(5): 360-366, maio 2005. ilus, tab
Artigo em Português | LILACS | ID: lil-400649

RESUMO

OBJETIVO: Este estudo tem por objetivo avaliar os efeitos, no seguimento de 6 meses, do transplante autólogo, transendocárdico, de células mononucleares da medula óssea (TACMMO), sobre os sintomas, capacidade de exercício, perfusão e contratilidade miocárdica nos portadores de cardiopatia isquêmica grave. MÉTODOS: Vinte e um pacientes foram incluídos neste estudo prospectivo (os 14 primeiros pacientes, grupo tratado; os 7 últimos pacientes, grupo controle). Inicialmente todos os indivíduos foram submetidos à avaliação clínica e laboratorial, teste ergométrico, ecocardiograma, cintilografia miocárdica e Holter de 24 horas. As CMMO foram isoladas, lavadas e diluídas em salina 0,9 por cento para injeção transendocárdica em áreas de miocárdio viável no grupo tratado, (15 injeções de 0,2 ml). Todos os pacientes foram reavaliados ao final de 2 e 6 meses de acompanhamento. RESULTADOS: Os dados demográficos e demais características não diferiram significativamente entre os grupos na avaliação inicial. Não foram observados eventos adversos maiores relacionados ao TACMMO. Ao final de 6 meses, houve redução da área isquêmica na imagem de perfusão nuclear (p=0,05) e melhora significativa dos sintomas, da capacidade funcional e da função global do ventrículo esquerdo. CONCLUSAO: Este estudo demonstra a segurança da realização de injeções transendocárdicas de CMMO em humanos com cardiopatia isquêmica associada a grave disfunção ventricular. Os efeitos observados em curto prazo foram mantidos até 6 meses de acompanhamento.


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Transplante de Medula Óssea , Tolerância ao Exercício/fisiologia , Revascularização Miocárdica , Isquemia Miocárdica/cirurgia , Transplante Autólogo , Estudos Epidemiológicos , Teste de Esforço , Coração , Contração Miocárdica , Isquemia Miocárdica , Neovascularização Fisiológica
15.
Tex Heart Inst J ; 31(3): 214-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15562839

RESUMO

Growing evidence suggests that transplantation of autologous bone-marrow mononuclear cells (ABMMNCs) can improve the perfusion and contractile function of ischemic myocardium. This procedure could potentially benefit transplant candidates awaiting a donor heart. To study the safety and feasibility of ABMMNC injection, we performed a prospective, nonrandomized, open-label study in 5 heart transplant candidates with severe ischemic heart failure. Each patient underwent baseline single-photon emission computed tomography, a ramp treadmill protocol, 2-dimensional echocardiography, 24-hour Holter monitoring, and signal-averaged electrocardiography, which were repeated at 2 and 6 months. Transendocardial delivery of ABMMNCs was done with the aid of electromechanical mapping to identify viable myocardium. Each patient received 15 ABMMNC injections of 0.2 cc each. There were no deaths, significant arrhythmias, or other major complications. The ABMMNC injection reduced the amount of ischemic myocardium (not statistically significant). More important, exercise test results improved significantly. Myocardial volume oxygen consumption increased from 10.6 +/- 3 mL/kg/min (baseline) to 16.3 +/- 7 mL/kg/min (2 months) and 23 +/- 7 mL/kg/min (6 months) (P = 0.0091). In 4 of the 5 cases, this was such an improvement that the patients were no longer eligible for cardiac transplantation. In addition, metabolic equivalents improved from 3.03 +/- 0.66 (baseline) to 4.65 +/- 1.99 (2 months) and 6.5 +/- 2.0 (6 months) (P = 0.0092). In conclusion, ABMMNC injections were performed safely and resulted in improved exercise capacity. This technique may hold promise as an alternative to medical management in patients with severe ischemic heart failure who are ineligible for conventional revascularization.


Assuntos
Transplante de Medula Óssea/métodos , Cateterismo Cardíaco , Insuficiência Cardíaca/cirurgia , Monócitos/transplante , Isquemia Miocárdica/complicações , Transplante de Medula Óssea/instrumentação , Endocárdio , Estudos de Viabilidade , Feminino , Seguimentos , Insuficiência Cardíaca/etiologia , Transplante de Coração , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Transplante Autólogo , Listas de Espera
16.
Circulation ; 110(11 Suppl 1): II213-8, 2004 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-15364865

RESUMO

BACKGROUND: We recently reported the safety and feasibility of autologous bone marrow mononuclear cell (ABMMNC) injection into areas of ischemic myocardium in patients with end-stage ischemic cardiomyopathy. The present study evaluated the safety and efficacy of this therapy at 6- and 12-month follow-up. METHODS AND RESULTS: Twenty patients with 6- and 12-month follow-up (11 treated subjects; 9 controls) were enrolled in this prospective, nonrandomized, open-label study. Complete clinical and laboratory evaluations as well as exercise stress (ramp treadmill), 2-dimensional Doppler echocardiography, single-photon emission computed tomography (SPECT) perfusion scanning, and 24-hour Holter monitoring were performed at baseline and follow-up. Transendocardial delivery of ABMMNCs was performed with the aid of electromechanical mapping to identify viable myocardium. Each patient received 15 ABMMNC injections of 0.2 mL each. At 6 and 12 months, total reversible defect, as measured by SPECT perfusion scanning, was significantly reduced in the treatment group as compared with the control group. At 12 months, exercise capacity was significantly improved in the treatment group. This improvement correlated well with monocyte, B-cell, hematopoietic progenitor cell, and early hemapoietic progenitor cell phenotypes. CONCLUSIONS: The 6- and 12-month follow-up data in this study suggest that transendocardial injection of ABMMNCs in patients with end-stage ischemic heart disease may produce a durable therapeutic effect and improve myocardial perfusion and exercise capacity.


Assuntos
Tolerância ao Exercício , Transplante de Células-Tronco Hematopoéticas , Isquemia Miocárdica/terapia , Idoso , Linfócitos B/citologia , Células da Medula Óssea/classificação , Diferenciação Celular , Linhagem da Célula , Ecocardiografia Doppler , Eletrocardiografia Ambulatorial , Teste de Esforço , Feminino , Seguimentos , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Monócitos/citologia , Isquemia Miocárdica/fisiopatologia , Consumo de Oxigênio , Estudos Prospectivos , Recidiva , Tomografia Computadorizada de Emissão de Fóton Único , Transplante Autólogo , Resultado do Tratamento , Disfunção Ventricular Esquerda/etiologia , Disfunção Ventricular Esquerda/terapia
17.
Circulation ; 107(18): 2294-302, 2003 May 13.
Artigo em Inglês | MEDLINE | ID: mdl-12707230

RESUMO

BACKGROUND: This study evaluated the hypothesis that transendocardial injections of autologous mononuclear bone marrow cells in patients with end-stage ischemic heart disease could safely promote neovascularization and improve perfusion and myocardial contractility. METHODS AND RESULTS: Twenty-one patients were enrolled in this prospective, nonrandomized, open-label study (first 14 patients, treatment; last 7 patients, control). Baseline evaluations included complete clinical and laboratory evaluations, exercise stress (ramp treadmill), 2D Doppler echocardiogram, single-photon emission computed tomography perfusion scan, and 24-hour Holter monitoring. Bone marrow mononuclear cells were harvested, isolated, washed, and resuspended in saline for injection by NOGA catheter (15 injections of 0.2 cc). Electromechanical mapping was used to identify viable myocardium (unipolar voltage > or =6.9 mV) for treatment. Treated and control patients underwent 2-month noninvasive follow-up, and treated patients alone underwent a 4-month invasive follow-up according to standard protocols and with the same procedures used as at baseline. Patient population demographics and exercise test variables did not differ significantly between the treatment and control groups; only serum creatinine and brain natriuretic peptide levels varied in laboratory evaluations at follow-up, being relatively higher in control patients. At 2 months, there was a significant reduction in total reversible defect and improvement in global left ventricular function within the treatment group and between the treatment and control groups (P=0.02) on quantitative single-photon emission computed tomography analysis. At 4 months, there was improvement in ejection fraction from a baseline of 20% to 29% (P=0.003) and a reduction in end-systolic volume (P=0.03) in the treated patients. Electromechanical mapping revealed significant mechanical improvement of the injected segments (P<0.0005) at 4 months after treatment. CONCLUSIONS: Thus, the present study demonstrates the relative safety of intramyocardial injections of bone marrow-derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.


Assuntos
Transplante de Medula Óssea , Endocárdio , Insuficiência Cardíaca/terapia , Isquemia Miocárdica/terapia , Transplante de Células-Tronco , Cateterismo Cardíaco , Angiografia Coronária , Circulação Coronária , Feminino , Seguimentos , Insuficiência Cardíaca/diagnóstico , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/diagnóstico , Neovascularização Fisiológica , Transplante de Células-Tronco/efeitos adversos , Tomografia Computadorizada de Emissão de Fóton Único , Transplante Autólogo , Função Ventricular Esquerda
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA